Why Cytokinetics Shares Plummeted
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Cytokinetics , a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases, tanked as much as 38% after reporting mid-stage top-line data from acute heart failure drug, omecamtiv mecarbil.
So what: According to the press releases, omecamtiv mecarbil, which Cytokinetics has partnered with Amgen in developing, failed to meet its primary endpoint of creating a significant difference from the placebo with regard to dyspnea system response (or in English, helping improve a patient's ability to breathe). Improvement in dyspnea was noted in the highest dosing group with little effect seen in the lowest dose. On the other hand, the drug proved to be as safe as the placebo and was well-tolerated.
Now what: Despite failing to meet its primary endpoint, all hope may not be lost. Amgen partnered with Cytokinetics for a reason, and there's a good chance it and Cytokinetics will focus on the higher dosage of omecamtiv mecarbil now that it's been proven safe. There's of course no guarantee that the drug will move into phase 3 trials, but it seems illogical that Amgen would expand its collaboration in June if it had the expectation of shelving omecamtiv mecarbil now. For Cytokinetics' shareholders, it's once again a watch and wait game with no FDA-approved drugs and the fate of omecamtiv mecarbil now up in the air.
If anything, Cytokinetics' failure today serves as a reminder that solid companies selling at depressed prices are what have consistently helped generations of the world's most successful investors preserve capital, minimize risk, and achieve long-term, market-trampling returns. If you'd like to learn about such company, read our free report: "The One REMARKABLE Stock to Own Now." Just click here to get started.
The article Why Cytokinetics Shares Plummeted originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.